In vitro pharmacological characterization of a new selective angiotensin AT(1) receptor antagonist, UR-7280

被引:29
作者
DeArriba, AF
GomezCasajus, LA
Cavalcanti, F
Almansa, C
GarciaRafanell, J
Forn, J
机构
[1] J URIACH & CIA SA,RES CTR,PHARMACOL LAB,BARCELONA,SPAIN
[2] J URIACH & CIA SA,RES CTR,CHEM LAB,BARCELONA,SPAIN
关键词
angiotensin AT(1) receptor; angiotensin II; binding; losartan; aorta; rabbit; UR-7280;
D O I
10.1016/S0014-2999(96)00794-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
UR-7280 (3-tert-butyl-1-propyl-5-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]-1H-pyrazole-4-carboxylic acid) is a new and potent angiotensin AT(1)-selective receptor antagonist. Binding studies in rat liver membranes showed that UR-7280 is an apparently competitive antagonist. However, in rabbit aorta this compound antagonized the angiotensin II-induced contractile response in an insurmountable way, causing a significant reduction of the maximal response. Additional binding studies evidenced that UR-7280 has a slowly reversible binding profile, consistent with its functional properties in rabbit aorta. The results obtained with a series of structural analogues of UR-7280 demonstrated a relationship between the size of the pyrazole 3-substituent and the surmountable or insurmountable mode of antagonism, indicating that this position may play a key role in the interaction between the antagonist and the angiotensin AT(1) receptor.
引用
收藏
页码:341 / 347
页数:7
相关论文
共 26 条
[1]   PHARMACOLOGY OF A POTENT LONG-ACTING IMIDAZOLE-5-ACRYLIC ACID ANGIOTENSIN AT(1) RECEPTOR ANTAGONIST [J].
AIYAR, N ;
BAKER, E ;
VICKERYCLARK, L ;
OHLSTEIN, EH ;
GELLAI, M ;
FREDRICKSON, TA ;
BROOKS, DP ;
WEINSTOCK, J ;
WEIDLEY, EF ;
EDWARDS, RM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 283 (1-3) :63-72
[2]  
BIRABEAU MA, 1984, PHARMACOL REV, V45, P205
[3]   IN-VITRO PHARMACOLOGY OF MK-996, A NEW POTENT AND SELECTIVE ANGIOTENSIN-II (AT(1)) RECEPTOR ANTAGONIST [J].
CHANG, RSL ;
BENDESKY, RJ ;
CHEN, TB ;
FAUST, KA ;
KLING, PJ ;
OMALLEY, SA ;
NAYLOR, EM ;
CHAKRAVARTY, PK ;
PATCHETT, AA ;
GREENLEE, WJ ;
CLINESCHMIDT, BV ;
LOTTI, VJ .
DRUG DEVELOPMENT RESEARCH, 1994, 32 (03) :161-171
[4]  
CHIU AT, 1990, J PHARMACOL EXP THER, V252, P711
[5]   PHARMACOLOGICAL PROFILE OF VALSARTAN - A POTENT, ORALLY-ACTIVE, NONPEPTIDE ANTAGONIST OF THE ANGIOTENSIN-II AT1-RECEPTOR SUBTYPE [J].
CRISCIONE, L ;
DEGASPARO, M ;
BUHLMAYER, P ;
WHITEBREAD, S ;
RAMJOUE, HPR ;
WOOD, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (02) :761-771
[6]   BMS-180560, AN INSURMOUNTABLE INHIBITOR OF ANGIOTENSIN II-STIMULATED RESPONSES - COMPARISON WITH LOSARTAN AND EXP3174 [J].
DICKINSON, KEJ ;
COHEN, RB ;
SKWISH, S ;
DELANEY, CL ;
SERAFINO, RP ;
POSS, MA ;
GU, Z ;
RYONO, DE ;
MORELAND, S ;
POWELL, JR .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (01) :179-189
[7]  
GADDUM J H, 1955, Q J Exp Physiol Cogn Med Sci, V40, P49
[8]  
GOMEZ LA, 1996, 16 SCI M INT SOC HYP
[9]   Drug therapy - Angiotensin receptors and their antagonists [J].
Goodfriend, TL ;
Elliott, ME ;
Catt, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (25) :1649-1654
[10]  
HARA M, 1995, EUR J PHARM-MOLEC PH, V289, P267